Comparison of the efficacy and cost-effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients.

MLA

Weill, D., and M. R. Zamora. “Comparison of the Efficacy and Cost-Effectiveness of Pre-Emptive Therapy as Directed by CMV Antigenemia and Prophylaxis with Ganciclovir in Lung Transplant Recipients.” The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation, vol. 19, no. 8, Aug. 2000, pp. 815–16. EBSCOhost, https://doi.org/10.1016/s1053-2498(00)00143-1.

APA

Weill, D., & Zamora, M. R. (2000). Comparison of the efficacy and cost-effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation, 19(8), 815–816. https://doi.org/10.1016/s1053-2498(00)00143-1

Chicago

Weill, D, and M R Zamora. 2000. “Comparison of the Efficacy and Cost-Effectiveness of Pre-Emptive Therapy as Directed by CMV Antigenemia and Prophylaxis with Ganciclovir in Lung Transplant Recipients.” The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 19 (8): 815–16. doi:10.1016/s1053-2498(00)00143-1.